{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["37"],"submitter":["Grall N"],"pubmed_abstract":["Secondary prophylaxis using inhaled colistin (IC) was implemented to prevent recurrences of Pseudomonas aeruginosa or extended-spectrum β-lactamase-producing Enterobacterales (ESBL-PE) pneumonia during the postoperative intensive care unit (ICU) stay after lung transplantation (LT). We evaluated the risk of emergence of colistin resistance in the respiratory tract during secondary IC prophylaxis. We conducted a prospective, single-centre, observational study of all adult patients who underwent LT between 1 July 2018 and 30 June 2019. IC was started and continued for at least 90 days for <i>P. aeruginosa</i> or ESBL-PE pneumonia. During the 90 days following LT, all respiratory samples were routinely tested for the presence of GNB of reduced susceptibility to colistin. Twenty-seven (38.6%) "],"journal":["Transplant international : official journal of the European Society for Organ Transplantation"],"pagination":["13545"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11799951"],"repository":["biostudies-literature"],"pubmed_title":["No Emergence of Colistin Resistance in the Respiratory Tract of Lung Transplant Patients Treated With Inhaled Colistin."],"pmcid":["PMC11799951"],"pubmed_authors":["Atchade E","Castier Y","Lortat-Jacob B","Bunel V","Grall N","Burdet C","Tran-Dinh A","Mal H","Assadi M","Mordant P","Esposito-Farese M","Tanaka S","Denamur E","Montravers P","Armand-Lefevre L","Garnier B","Messika J","Gueye S","Petitjean M"],"additional_accession":[]},"is_claimable":false,"name":"No Emergence of Colistin Resistance in the Respiratory Tract of Lung Transplant Patients Treated With Inhaled Colistin.","description":"Secondary prophylaxis using inhaled colistin (IC) was implemented to prevent recurrences of Pseudomonas aeruginosa or extended-spectrum β-lactamase-producing Enterobacterales (ESBL-PE) pneumonia during the postoperative intensive care unit (ICU) stay after lung transplantation (LT). We evaluated the risk of emergence of colistin resistance in the respiratory tract during secondary IC prophylaxis. We conducted a prospective, single-centre, observational study of all adult patients who underwent LT between 1 July 2018 and 30 June 2019. IC was started and continued for at least 90 days for <i>P. aeruginosa</i> or ESBL-PE pneumonia. During the 90 days following LT, all respiratory samples were routinely tested for the presence of GNB of reduced susceptibility to colistin. Twenty-seven (38.6%) ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2025-04-04T01:36:09.129Z","creation":"2025-04-04T01:36:09.129Z"},"accession":"S-EPMC11799951","cross_references":{"pubmed":["39916770"],"doi":["10.3389/ti.2024.13545"]}}